Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Total revenue	$ 6,920	$ 461	$ 9,148	$ 8,859
Operating expenses:
Cost of product sales	(15)		(15)
Research and development expenses	(5,601)	(40,804)	(21,213)	(60,800)
Selling, general and administrative expenses	(18,503)	(12,582)	(45,339)	(31,555)
Total operating expenses	(24,119)	(53,386)	(66,567)	(92,355)
Loss from operations	(17,199)	(52,925)	(57,419)	(83,496)
Other income (expense):
Other income (expense), net	(10)	(54)	116	(172)
Interest income	94	11	176	39
Interest expense	(709)	(8)	(2,512)	(19)
Loss before income taxes	(17,824)	(52,976)	(59,639)	(83,648)
Income tax benefit (expense)	29	151	(80)	(307)
Net loss	$ (17,795)	$ (52,825)	$ (59,719)	$ (83,955)
Loss per share
Basic and Diluted ($ per share)	$ (0.24)	$ (0.90)	$ (0.83)	$ (1.85)
Weighted average number of shares:
Basic and Diluted	75,161,192	58,442,987	72,153,405	45,369,040
Product revenue, net
Revenues:
Total revenue	$ 1,445		$ 1,445
Collaboration revenue
Revenues:
Total revenue	5,051		6,051	$ 6,500
Research premium and grant revenue
Revenues:
Total revenue	$ 424	$ 461	$ 1,652	$ 2,359